Renaissance Technologies’s Enzo Biochem, Inc. ENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,082,229
Closed -$770K 3999
2025
Q1
$770K Sell
2,082,229
-285,314
-12% -$158K ﹤0.01% 2555
2024
Q4
$1.69M Sell
2,367,543
-159,986
-6% -$166K ﹤0.01% 2156
2024
Q3
$2.83M Buy
2,527,529
+27,983
+1% +$31.3K ﹤0.01% 1792
2024
Q2
$2.72M Buy
2,499,546
+64,417
+3% +$72.6K ﹤0.01% 1679
2024
Q1
$3.09M Sell
2,435,129
-44,066
-2% -$58.2K ﹤0.01% 1751
2023
Q4
$3.45M Sell
2,479,195
-76,869
-3% -$102K 0.01% 1587
2023
Q3
$3.58M Sell
2,556,064
-148,800
-6% -$224K 0.01% 1488
2023
Q2
$4.98M Sell
2,704,864
-65,200
-2% -$151K 0.01% 1433
2023
Q1
$6.73M Sell
2,770,064
-43,900
-2% -$65.3K 0.01% 1309
2022
Q4
$4.02M Sell
2,813,964
-95,700
-3% -$186K 0.01% 1646
2022
Q3
$6.49M Sell
2,909,664
-106,500
-4% -$257K 0.01% 1290
2022
Q2
$6.24M Buy
3,016,164
+5,000
+0.2% +$12.4K 0.01% 1397
2022
Q1
$8.73M Sell
3,011,164
-83,600
-3% -$268K 0.01% 1214
2021
Q4
$9.93M Sell
3,094,764
-115,300
-4% -$393K 0.01% 1076
2021
Q3
$11.4M Sell
3,210,064
-49,200
-2% -$164K 0.01% 951
2021
Q2
$10.3M Sell
3,259,264
-81,600
-2% -$257K 0.01% 1146
2021
Q1
$11.5M Sell
3,340,864
-215,359
-6% -$670K 0.01% 1103
2020
Q4
$8.96M Sell
3,556,223
-30,500
-0.9% -$66.4K 0.01% 1236
2020
Q3
$7.57M Buy
3,586,723
+121,445
+4% +$289K 0.01% 1321
2020
Q2
$7.76M Buy
3,465,278
+153,300
+5% +$394K 0.01% 1379
2020
Q1
$8.38M Sell
3,311,978
-41,830
-1% -$103K 0.01% 1269
2019
Q4
$8.82M Buy
3,353,808
+54,245
+2% +$162K 0.01% 1523
2019
Q3
$11.9M Buy
3,299,563
+48,530
+1% +$172K 0.01% 1279
2019
Q2
$11M Buy
3,251,033
+65,804
+2% +$232K 0.01% 1343
2019
Q1
$8.7M Buy
3,185,229
+97,559
+3% +$319K 0.01% 1455
2018
Q4
$8.58M Buy
3,087,670
+124,970
+4% +$409K 0.01% 1395
2018
Q3
$12.2M Sell
2,962,700
-39,500
-1% -$179K 0.01% 1228
2018
Q2
$15.6M Buy
3,002,200
+25,300
+0.8% +$154K 0.02% 1085
2018
Q1
$16.3M Buy
2,976,900
+641,100
+27% +$4.52M 0.02% 1061
2017
Q4
$19M Buy
2,335,800
+197,900
+9% +$1.89M 0.02% 970
2017
Q3
$22.4M Buy
2,137,900
+68,300
+3% +$758K 0.03% 822
2017
Q2
$22.8M Buy
2,069,600
+27,200
+1% +$253K 0.03% 770
2017
Q1
$17.1M Buy
2,042,400
+76,900
+4% +$542K 0.02% 903
2016
Q4
$13.6M Buy
1,965,500
+8,132
+0.4% +$51.9K 0.02% 1028
2016
Q3
$9.96M Buy
1,957,368
+90,387
+5% +$540K 0.02% 1151
2016
Q2
$11.1M Buy
1,866,981
+417,081
+29% +$2.31M 0.02% 1074
2016
Q1
$6.6M Buy
1,449,900
+196,800
+16% +$876K 0.01% 1431
2015
Q4
$5.64M Buy
1,253,100
+139,900
+13% +$591K 0.01% 1392
2015
Q3
$3.53M Sell
1,113,200
-66,952
-6% -$203K 0.01% 1622
2015
Q2
$3.58M Sell
1,180,152
-33,491
-3% -$94.1K 0.01% 1661
2015
Q1
$3.58M Buy
1,213,643
+269,306
+29% +$882K 0.01% 1572
2014
Q4
$4.19M Buy
944,337
+15,537
+2% +$74.1K 0.01% 1377
2014
Q3
$4.78M Buy
928,800
+364,982
+65% +$1.95M 0.01% 1189
2014
Q2
$2.96M Buy
563,818
+115,937
+26% +$501K 0.01% 1519
2014
Q1
$1.86M Buy
447,881
+102,244
+30% +$350K ﹤0.01% 1807
2013
Q4
$1.01M Buy
345,637
+61,737
+22% +$153K ﹤0.01% 2073
2013
Q3
$715K Buy
283,900
+25,400
+10% +$60.2K ﹤0.01% 2161
2013
Q2
$538K Buy
+258,500
New +$571K ﹤0.01% 2209

Other funds holding ENZ

Renaissance Technologies's ENZ Position: Q2 2025 in Review

Renaissance Technologies sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 2,082,229 shares — an estimated $770K sold.

Renaissance Technologies first reported a position in ENZ in Q2 2013 and held it in 48 quarters. The position peaked at $22.8M in Q2 2017. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

  • Renaissance Technologies reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
  • Renaissance Technologies sold 2,082,229 Enzo Biochem, Inc. shares in Q2 2025, an estimated $770K.
  • Renaissance Technologies first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 48 quarters.
  • Renaissance Technologies's Enzo Biochem, Inc. position peaked at $22.8M in Q2 2017.
  • 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.